Survival O
benefits O
of O
dose O
- O
dense O
early O
postoperative O
intraperitoneal O
chemotherapy O
in O
front O
- O
line O
therapy O
for O
advanced O
ovarian O
cancer O
: O
a O
randomised B-STYPE
controlled I-STYPE
study I-STYPE
Survival O
benefits O
of O
dose O
- O
dense O
early O
postoperative O
intraperitoneal O
chemotherapy O
in O
front O
- O
line O
therapy O
for O
advanced O
ovarian O
cancer O
: O
a O
randomised B-STYPE
controlled I-STYPE
study I-STYPE
6 O
August O
2019 O
6 O
August O
2019 O
TingyanShi B-AUTH

Survival O
benefits O
of O
dose O
- O
dense O
early O
postoperative O
intraperitoneal O
chemotherapy O
in O
front O
- O
line O
therapy O
for O
advanced O
ovarian O
cancer O
: O
a O
randomised B-STYPE
controlled I-STYPE
study I-STYPE
6 O
August O
2019 O

Survival O
benefits O
of O
dose O
- O
dense O
early O
postoperative O
intraperitoneal O
chemotherapy O
in O
front O
- O
line O
therapy O
for O
advanced O
ovarian O
cancer O
: O
a O
randomised B-STYPE
controlled I-STYPE
study I-STYPE
TingyanShi B-AUTH

China O
Shanghai O
China O
Survival O
benefits O
of O
dose O
- O
dense O
early O
postoperative O
intraperitoneal O
chemotherapy O
in O
front O
- O
line O
therapy O
for O
advanced O
ovarian O
cancer O
: O
a O
randomised B-STYPE
controlled I-STYPE
study I-STYPE
6 O
August O
2019 O
6 O
August O
2019 O
6 O
August O
2019 O
10.1038 O
/ O
s41416 O
- O
019 O
- O
0543 O
- O
1 O
Received O
: O
3 O
April O
2019 O
Revised O
: O
9 O
July O
2019 O
Accepted O
: O
18 O
July O
2019 O

To O
date O
, O
three O
randomised O
phase O
3 O
clinical O
trials O
have O
demonstrated O
that O
intraperitoneal O
( O
IP O
) O
chemotherapy O
is O
an O
effective O
management O
for O
epithelial O
ovarian O
cancer O
after O
primary O
optimal O
debulking O
surgery O
. O
[ O
1][2][3 O
] O
However O
, O
the O
fourth O
phase O
3 O
trial O
, O
GOG252 O
that O
reduced O
the O
cisplatin O
dose O
from O
100 O
mg O
/ O
m O
2 O
to O
75 O
mg O
/ O
m O
2 O
neither O
showed O
a O
survival O
benefit O
in O
IP O
Carboplatin O
nor O
in O
IP O
Cisplatin O
, O
4 O
which O
highlights O
the O
controversy O
of O
IP O
chemotherapy O
in O
ovarian O
cancer O
. O
Our O
recent O
study O
reported O
disease O
progression O
delayed O
by O
additional O
dose O
- O
dense O
early O
postoperative O
intraperitoneal O
chemotherapy O
( O
DD O
- O
EPIC O
) O
with O
weekly O
cisplatin O
and O
etoposide O
( O
AICE O
trial O
) O
in O
the O
front O
- O
line O
setting O
. O
5 O
The O
primary O
endpoint O
of O
the O
AICE O
phase O
2 O
trial O
showed O
a O
28 O
% O
increase O
in O
12-month O
nonprogression O
rate O
in O
ovarian O
cancer O
patients O
in O
favour O
of O
the O
DD O
- O
EPIC O
group O
[ O
hazard O
ratio O
( O
HR O
) O
0.48 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
0.27 O
- O
0.82 O
, O
P O
= O
0.005 O
] O
. O
Despite O
the O
increased O
toxicity O
in O
the O
DD O
- O
EPIC O
group O
, O
most O
toxicities O
were O
acceptable O
, O
and O
the O
completion O
rate O
was O
much O
higher O
than O
that O
in O
GOG172 O
, O
with O
the O
infection O
rate O
11.6 O
% O
in O
AICE O
vs. O
16 O
% O
in O
GOG172 O
, O
and O
a O
completion O
rate O
of O
IP O
chemotherapy O
90.6 O
% O
vs. O
42 O
% O
, O
respectively O
. O
2,5 O
The O
mean O
inpatient O
cost O
in O
the O
DD O
- O
EPIC O
group O
was O
not O
much O
higher O
than O
that O
in O
the O
control O
group O
( O
$ O
9338.2 O
vs. O
$ O
7424.4 O
) O
. O

The O
AICE O
trial O
was O
also O
designed O
to O
detect O
the O
improvement O
of O
progression O
- O
free O
and O
overall O
survival O
( O
OS O
) O
. O
Here O
, O
we O
present O
the O
final O
OS O
and O
updated O
PFS B-METRIC
data O
. O

The O
AICE O
study O
was O
an O
investigator B-STYPE
- I-STYPE
initiated I-STYPE
multicentre I-STYPE
, I-STYPE
randomised I-STYPE
, I-STYPE
unblinded I-STYPE
, I-STYPE
controlled I-STYPE
, I-STYPE
phase I-STYPE
2 I-STYPE
trial I-STYPE
to O
assess O
the O
efficacy O
and O
safety O
of O
DD B-DESC
- I-DESC
EPIC I-DESC
in O
the O
front O
- O
line O
therapy O
of O
advanced O
ovarian O
cancer O
. O
The O
study O
design O
and O
the O
detailed O
inclusion O
and O
exclusion O
criteria O
, O
as O
well O
as O
the O
baseline O
characteristics O
and O
primary O
outcome O
results O
have O
been O
previously O
described O
. O
5 O
Briefly O
, O
eligible O
patients O
were O
aged O
18 O
- O
75 O
years O
; O
with O
stage O
IIIC O
and O
IV O
primary O
epithelial O
ovarian O
, O
fallopian O
tube O
or O
peritoneal O
cancer O
, O
excluding O
lymph O
node O
metastasis O
alone O
; O
an O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
performance O
status O
of O
0 O
- O
2 O
; O
no O
more O
than O
three O
cycles O
of O
chemotherapy O
prior O
to O
surgery O
; O
with O
optimal O
( O
≤1 O
cm O
residual O
disease O
) O
debulking O
surgery O
. O
Randomisation O
was O
done O
using O
1:1 O
allocation O
, O
and O
was O
performed O
after O
debulking O
surgery O
. O
DD B-DESC
- I-DESC
EPIC I-DESC
was O
defined O
to O
be O
started O
at O
5 O
- O
10 O
days O
after O
surgery O
, O
and O
no O
more O
than O
14 O
days O
postoperative O
for O
those O
with O
bowel O
resection O
. O

After O
randomisation O
, O
patients O
received O
either O
four B-DOSAGE
doses I-DOSAGE
of I-DOSAGE
weekly I-DOSAGE
DD B-DESC
- I-DESC
EPIC I-DESC
with O
cisplatin B-DESC
50 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
and O
etoposide B-DESC
100 B-DOSAGE
mg/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
followed O
by O
six B-DOSAGE
cycles I-DOSAGE
of O
IV O
carboplatin B-DESC
AUC O
5 O
and O
paclitaxel B-DESC
175 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
or O
docetaxel B-DESC
60 O
- O
75 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
every I-DOSAGE
3 I-DOSAGE
weeks I-DOSAGE
( O
the O
DD O
- O
EPIC O
group O
) O
or O
standard O
six B-DOSAGE
cycles I-DOSAGE
of O
IV O
carboplatin B-DESC
AUC O
5 O
and O
paclitaxel B-DESC
175 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
or O
docetaxel B-DESC
60 B-DOSAGE
- I-DOSAGE
75 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
every I-DOSAGE
3 I-DOSAGE
weeks I-DOSAGE
( O
the O
IV B-DESC
group I-DESC
) O
. O

Each O
patient O
was O
followed O
every O
3 O
months O
over O
the O
first O
5 O
years O
, O
and O
then O
every O
6 O
months O
thereafter O
, O
during O
which O
physical O
examination O
, O
CA125 O
levels O
and O
radiological O
images O
( O
ultrasound O
, O
computed O
tomography O
or O
magnetic O
resonance O
imaging O
) O
were O
performed O
. O
Progression O
was O
defined O
by O
one O
or O
more O
of O
the O
following O
items O
: O
physical O
examination O
, O
elevated O
CA125 O
levels O
according O
to O
the O
Gynecologic O
Oncology O
Intergroup O
criteria O
and/or O
radiological O
images O
. O
Each O
progression O
event O
was O
confirmed O
by O
centre O
principle O
investigators O
. O

The O
trial O
was O
structured O
a O
priori O
to O
assess O
PFS B-METRIC
and O
OS O
, O
as O
the O
secondary O
outcomes O
. O
PFS B-METRIC
was O
defined O
as O
the O
time O
from O
randomisation O
to O
first O
recurrence O
/ O
progression O
, O
or O
last O
follow O
- O
up O
, O
or O
death O
from O
ovarian O
cancer O
, O
whichever O
came O
first O
. O
The O
data O
regarding O
patients O
with O
no O
evidence O
of O
recurrence O
or O
death O
from O
ovarian O
cancer O
were O
censored O
at O
the O
date O
of O
last O
follow O
- O
up O
. O

The O
comparisons O
and O
distributions O
of O
characteristics O
between O
the O
two O
groups O
and O
subgroups O
were O
conducted O
with O
the O
Chisquare O
or O
Student O
's O
or O
Mann O
- O
Whitney O
U O
tests O
. O
Median O
survival O
was O
evaluated O
using O
the O
Kaplan O
- O
Meier O
method O
, O
and O
a O
log O
- O
rank O
test O
was O
used O
to O
compare O
survival O
between O
two O
randomised O
groups O
. O
Treatment O
effects O
were O
estimated O
by O
using O
the O
Cox O
regression O
model O
when O
proportional O
hazards O
could O
be O
assumed O
. O
Because O
there O
was O
no O
prespecified O
plan O
to O
stratify O
or O
adjust O
for O
multiple O
comparisons O
, O
a O
multivariable O
analysis O
was O
performed O
to O
evaluate O
efficacy O
outcomes O
with O
the O
adjustment O
for O
the O
important O
baseline O
confounders O
, O
such O
as O
FIGO O
stage O
, O
neoadjuvant O
chemotherapy O
and O
residual O
diseases O
. O
The O
previous O
analysis O
of O
12-month O
nonprogression O
rate O
has O
been O
conducted O
( O
two O
- O
sided O
α O
= O
0.05 O
) O
. O
5 O
Here O
, O
prespecified O
PFS B-METRIC
and O
OS O
analyses O
were O
performed O
after O
sufficient O
follow O
- O
up O
for O
the O
observation O
of O
160 O
( O
80 O
% O
) O
events O
of O
disease O
progression O
, O
or O
death O
from O
ovarian O
cancer O
, O
using O
a O
two O
- O
sided O
α O
of O
0.05 O
. O

Censored O
on O
September O
10 O
, O
2018 O
( O
3 O
years O
after O
the O
last O
patient O
enrolled O
) O
, O
the O
median O
follow O
- O
up O
time O
was O
69.1 O
months O
( O
interquartile O
range O
, O
53.1 O
- O
83.9 O
) O
. O
The O
median O
time O
to O
the O
first O
cycle O
of O
standard O
IV O
chemotherapy O
since O
primary O
surgery O
were O
49 O
days O
and O
15 O
days O
in O
the O
DD B-DESC
- I-DESC
EPIC I-DESC
and O
IV B-DESC
group I-DESC
, O
respectively O
( O
Student O
's O
t O
test O
, O
P O
< O
0.001 O
) O
, O
but O
the O
period O
of O
front O
- O
line O
chemotherapy O
was O
similar O
between O
the O
two O
groups O
, O
with O
only O
a O
0.2-month O
increase O
in O
the O
DD B-DESC
- I-DESC
EPIC I-DESC
group O
. O

Totally O
, O
122 O
patients O
( O
56.3 O
% O
) O
died O
from O
ovarian O
cancer O
: O
54 O
( O
50.9 O
% O
) O
of O
those O
in O
the O
DD B-DESC
- I-DESC
EPIC I-DESC
group O
and O
68 O
( O
62.4 O
% O
) O
of O
those O
in O
the O
IV B-DESC
group I-DESC
, O
respectively O
. O
The O
median O
overall O
survival O
was O
67.5 O
( O
95 O
% O
CI O
57.0 O
- O
78.1 O
) O
months O
in O
the O
DD B-DESC
- I-DESC
EPIC I-DESC
group O
and O
46.3 O
( O
95 O
% O
CI O
35.1 O
- O
57.5 O
) O
months O
in O
the O
IV B-DESC
group I-DESC
, O
a O
difference O
of O
21.2 O
months O
. O
The O
probability O
rate O
of O
overall O
survival O
at O
5 O
years O
was O
61.0 O
% O
with O
DD B-DESC
- I-DESC
EPIC I-DESC
and O
38.2 O
% O
with O
IV B-DESC
chemotherapy I-DESC
alone I-DESC
( O
HR O
for O
death O
from O
ovarian O
cancer O
, O
0.70 O
; O
95 O
% O
CI O
, O
0.49 O
- O
1.00 O
; O
P O
= O
0.047 O
; O
Fig O
. O
1a O
) O
. O
Patients O
in O
the O
DD B-DESC
- I-DESC
EPIC I-DESC
group O
showed O
significantly O
prolonged O
PFS B-METRIC
compared O
with O
those O
in O
the O
IV B-DESC
group I-DESC
( O
the O
estimated O
rate O
of O
PFS  B-METRIC
at O
5 B-RESULTS
years I-RESULTS
, I-RESULTS
26.0 I-RESULTS
% I-RESULTS
vs. I-RESULTS
8.5 I-RESULTS
% I-RESULTS
; I-RESULTS
HR I-RESULTS
0.64 I-RESULTS
, I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
0.47 I-RESULTS
- I-RESULTS
0.86 I-RESULTS
, I-RESULTS
P I-RESULTS
= I-RESULTS
0.003 I-RESULTS
; I-RESULTS
Fig I-RESULTS
. I-RESULTS
1b I-RESULTS
) I-RESULTS
. O
Similar O
findings O
were O
observed O
in O
the O
time O
to O
first O
and O
second O
subsequent O
anticancer O
therapies O
( O
Supplementary O
Figs O
. O
S1 O
, O
S2 O
) O
. O
The O
survival O
benefit O
of O
DD B-DESC
- I-DESC
EPIC I-DESC
remained O
after O
the O
adjustment O
for O
FIGO O
stage O
, O
neoadjuvant O
chemotherapy O
and O
residual O
disease O
( O
Supplementary O
Table O
S1 O
) O
. O
Subgroup O
analyses O
of O
overall O
survival O
( O
Fig O
. O
1c O
) O
and O
progression B-METRIC
- I-METRIC
free I-METRIC
survival I-METRIC
( O
Supplementary O
Table O
S2 O
) O
showed O
that O
the O
benefit O
of O
DD B-DESC
- I-DESC
EPIC I-DESC
was O
consistent O
across O
most O
of O
the O
baseline O
risk O
factors O
and O
post O
hoc O
subgroups O
. O

The O
maintenance O
therapy O
and O
the O
second O
- O
line O
therapy O
are O
listed O
in O
Supplementary O
Table O
S3 O
. O
During O
the O
extended O
follow O
- O
up O
of O
overall O
survival O
, O
we O
did O
not O
observe O
any O
chemotherapeutic O
- O
related O
adverse O
events O
added O
. O